SCHEMBL1026693

SCHEMBL1026693

CC(C)(C)N(C(=O)O)c1cccc(N)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
CYP3A4 P08684 2/20 0.41
CASP1 P29466 1/20 0.41
RECQL P46063 1/20 0.41
DDX3X O00571 2/20 0.41
PBRM1 Q86U86 1/20 0.41
NPSR1 Q6W5P4 1/20 0.38
NPC1 O15118 1/20 0.36
MITF O75030 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1027143 0.87 FFAR1 (0.49) ALDH1A1DDX3XPBRM1
SCHEMBL1026191 0.87 MAOA (0.50) ALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL17221855 0.83 TDP1 (0.34) ALDH1A1CASP1KDM4ETDP1MEN1
SCHEMBL1026880 0.83 THRA (0.39) ALDH1A1NPSR1KMT2A
SCHEMBL1026509 0.83 CYP1A2 (0.36) ALDH1A1CYP3A4NPC1LMNAMEN1
SCHEMBL1024327 0.82 PTGS1 (0.53) ALDH1A1NPSR1POLBSMN1; SMN2KDM4E
SCHEMBL1555330 0.81 ALDH1A1 (0.50) ALDH1A1CYP3A4LMNASMN1; SMN2CA12
SCHEMBL1025196 0.80 FFAR1 (0.36) ALDH1A1CYP3A4RECQLSMN1; SMN2HDAC3
SCHEMBL17728900 0.79 HTR3E (0.44) ALDH1A1NPSR1NPC1LMNASMN1; SMN2
SCHEMBL7379122 0.79 RXRA (0.45) ALDH1A1CYP3A4RECQLNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116882-A1 NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2024-04-11 US disclosed
EP-4286374-A1 NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF Txinno Bioscience Inc. (KR) 2023-12-06 EP disclosed
US-20230027026-A1 FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF BLUEPRINT MEDICINES CORPORATION 2023-01-26 US disclosed
WO-2022164249-A1 NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF 주식회사 티씨노바이오사이언스 2022-08-04 WO disclosed
US-20220153730-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-19 US disclosed
US-20210300911-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-09-30 US disclosed
US-10981903-B2 Inhibitors of c-Jun-N-terminal kinase (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-04-20 US disclosed
WO-2021062327-A1 FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF JUBILANT BIOSYS LIMITED (IN) 2021-04-01 WO disclosed
US-10787436-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-09-29 US disclosed
US-20200087295-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-03-19 US disclosed
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2014-12-04 US disclosed
US-20140309249-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) Dana-Farber Cancer Intitute, Inc. (US) 2014-10-16 US disclosed
US-20130172550-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2013-07-04 US disclosed
EP-2597088-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2013-05-29 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
US-5538652-A OXIDATION, CORROSION AND WEAR RESISTANT EXTREME PRESSURE OIL ADDITIVES FOR ENGINE LUBRICANTS MOBIL OIL CORPORATION (US) 1996-07-23 US disclosed
US-RE32316-E HERBICIDES RHONE-POULENC AGROCHIMIE (FR) 1986-12-30 US disclosed
US-3983168-A HERBICIDES MOBIL OIL CORPORATION (US) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 ALDH1A1 625/4885CYP3A4 1991/4885CASP1 2141/4885
US-10981903-B2 Inhibitors of c-Jun-N-terminal kinase (JNK) CNKSR1, MAPK1, MAP3K1 ALDH1A1 2480/4885CYP3A4 3824/4885CASP1 351/4885
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 ALDH1A1 3019/4885CYP3A4 1142/4885CASP1 2300/4885
US-20210300911-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 ALDH1A1 2480/4885CYP3A4 3824/4885CASP1 351/4885
US-20130172550-A1 P2X4 RECEPTOR ANTAGONIST P2RX4, P2RX3, P2RX7 ALDH1A1 2732/4885CYP3A4 759/4885CASP1 1531/4885
US-20200087295-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 ALDH1A1 2480/4885CYP3A4 3824/4885CASP1 351/4885
US-20220153730-A9 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 ALDH1A1 2480/4885CYP3A4 3824/4885CASP1 351/4885
US-20240116882-A1 NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF ENPP1, ENPP3, TPP1 ALDH1A1 1912/4885CYP3A4 2671/4885CASP1 1550/4885
US-20140309249-A1 INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) CNKSR1, MAPK1, MAP3K1 ALDH1A1 2480/4885CYP3A4 3824/4885CASP1 351/4885
US-10787436-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) CDK7, CDK9, CDK6 ALDH1A1 4000/4885CYP3A4 911/4885CASP1 123/4885
US-20230027026-A1 FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF DPYD, TYMP, TYMS ALDH1A1 953/4885CYP3A4 201/4885CASP1 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.